The purpose of this multi-country, retrospective data collection study (chart review) is to describe the effectiveness and safety of caplacizumab in pediatric patients with iTTP.

Pediatric patients who received caplacizumab will be identified for enrollment in the chart review. The eligibility period starts on August 30, 2018 in the United Kingdom (UK) and France and February 6, 2019 for the United States (US).

Data collection is fully retrospective and will be anchored to the patient's index event date. The index event date is defined as the date the patient initiated caplacizumab treatment. The study period begins at the index date and ends at the earliest date of chart abstraction initiation, 12 weeks after last dose of caplacizumab treatment, date of death, or loss to follow-upwhich ever comes first .

Inclusion Criteria:

• Patient's aged ≤18 years at start of caplacizumab treatment initiation
• Patient has a diagnosis of iTTP documented in the medical records
• Patient was treated with caplacizumab within the eligibility period

Exclusion Criteria:

• Patient declined use of data for study (where local regulations require patient notification of planned study)
• Patient's medical chart is missing or not retrievable

Pediatric patients with Immune-mediated Thrombotic Thrombocytopenic Purpura treated with Caplacizumab

Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org